Finder makes money from featured partners, but editorial opinions are our own.

How to buy GlaxoSmithKline (GSK) shares in Australia

Learn how to easily invest in GlaxoSmithKline shares.

GlaxoSmithKline PLC ADR is a drug manufacturers - general business with stocks listed in the US. GlaxoSmithKline shares (GSK) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was US$39.75 – a decrease of 2.24% over the previous week. Here's how to invest if you're based in Australia.

How to buy shares in GlaxoSmithKline

  1. Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for GlaxoSmithKline. Find the share by name or ticker symbol: GSK. Research its history to confirm it's a solid investment that matches your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until GlaxoSmithKline reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$39.27, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of GlaxoSmithKline, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of GlaxoSmithKline. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.

GlaxoSmithKline stock price (NYSE:GSK)

Use our graph to track the performance of GSK stocks over time.

Have GlaxoSmithKline's shares ever split?

GlaxoSmithKline's shares were split on a 1226:1000 basis on 21 July 2022. So if you had owned 1000 shares the day before the split, the next day you would own 1226 shares. This wouldn't directly have changed the overall worth of your GlaxoSmithKline shares – just the quantity. However, indirectly, the new 18.4% lower share price could have impacted the market appetite for GlaxoSmithKline shares which in turn could have impacted GlaxoSmithKline's share price.

GlaxoSmithKline shares at a glance

Information last updated 2024-04-18.
52-week rangeUS$32.3451 - US$43.84
50-day moving average US$41.9664
200-day moving average US$37.7253
Target priceUS$45.32
PE ratio 13.1271
Dividend yield US$0.58 (3.7%)
Earnings per share (TTM) US$2.99

GlaxoSmithKline share growth calculator

US$

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

GlaxoSmithKline price performance over time

Historical closes compared with the last close of $39.75

1 week (2024-04-12) -2.24%
1 month (2024-03-20) -5.20%
3 months (2024-01-19) 0.18%
6 months (2023-10-20) 11.72%
1 year (2023-04-20) 9.02%
2 years (2022-04-20) 6.31%
3 years (2021-04-20) 29.27%
5 years (2019-04-18) 22.29%

Is it a good time to buy GlaxoSmithKline stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is GlaxoSmithKline under- or over-valued?

Valuing GlaxoSmithKline stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of GlaxoSmithKline's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

GlaxoSmithKline's P/E ratio

GlaxoSmithKline's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, GlaxoSmithKline shares trade at around 13x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

GlaxoSmithKline's PEG ratio

GlaxoSmithKline's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.0866. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into GlaxoSmithKline's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

GlaxoSmithKline's EBITDA

GlaxoSmithKline's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$10.3 billion (£8.3 billion).

The EBITDA is a measure of a GlaxoSmithKline's overall financial performance and is widely used to measure stock profitability.

GlaxoSmithKline share price volatility

Over the last 12 months, GlaxoSmithKline's shares have ranged in value from as little as US$32.3451 up to US$43.84. A popular way to gauge a stock's volatility is its "beta".

Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while GlaxoSmithKline's is 0.268. This would suggest that GlaxoSmithKline's shares are less volatile than average (for this exchange).

GlaxoSmithKline financials

Revenue TTM US$30.3 billion
Operating margin TTM 20.36%
Gross profit TTM US$19.9 billion
Return on assets TTM 8.81%
Return on equity TTM 46.38%
Profit margin 16.25%
Book value 3.29
Market capitalisation US$81.2 billion

TTM: trailing 12 months

GlaxoSmithKline share dividends

38%

Dividend payout ratio: 37.56% of net profits

Recently GlaxoSmithKline has paid out, on average, around 37.56% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.7% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), GlaxoSmithKline shareholders could enjoy a 3.7% return on their shares, in the form of dividend payments. In GlaxoSmithKline's case, that would currently equate to about $0.58 per share.

While GlaxoSmithKline's payout ratio might seem fairly standard, it's worth remembering that GlaxoSmithKline may be investing much of the rest of its net profits in future growth.

GlaxoSmithKline's most recent dividend payout was on 10 April 2024. The latest dividend was paid out to all shareholders who bought their shares by 21 February 2024 (the "ex-dividend date").

GlaxoSmithKline overview

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Stocks similar to GlaxoSmithKline

Frequently asked questions

More guides on Finder

Ask a Question

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our 1. Terms Of Service and 6. Finder Group Privacy & Cookies Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site